We can’t show the full text here under this license. Use the link below to read it at the source.
GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes
GLP-1 Receptor Agonist Treatment and Heart and Kidney Health in People Aged 80 and Older with Type 2 Diabetes
AI simplified
Abstract
Among 11,464 matched patients aged 80 years and older, GLP-1 RA users had a lower risk of major adverse cardiovascular events compared to DPP4i users.
- GLP-1 RA users experienced a 14% reduction in the risk of major adverse cardiovascular events.
- The risk of major adverse kidney events was also reduced by 14% in GLP-1 RA users.
- All-cause hospitalization rates were 9% lower for patients using GLP-1 RAs compared to those on DPP4is.
- A significant decrease of 18% in all-cause mortality was observed among GLP-1 RA users.
- No significant differences in heart failure or bone fracture rates were noted between the two groups.
AI simplified
Key numbers
14.5%
Decrease in All-Cause Mortality
Mortality rates for GLP-1 RA users vs. DPP4i users.
20.9%
Decrease in Major Adverse Cardiovascular Events
Event rates for GLP-1 RA users vs. DPP4i users.
20.9%
Hospitalization Rate
Hospitalization rates in GLP-1 RA users vs. DPP4i users.